PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026Prostate Cancer and Prostatic Diseases2 citationsOpen Access

Mitochondrial dysfunction in urologic disease

AAAlexis E. AdrianNBNatalie BoucherKMKevin T. McVary

Key Points

  • This review aims to summarize existing literature on mitochondrial dysfunction in relation to lower urinary tract symptoms.
  • Literature search conducted using PubMed with specific keywords related to LUTS and mitochondria.
  • Focus on clinical or human studies, excluding pre-2025 publications and conditions with insufficient literature.
  • Disease-specific searches performed, excluding urologic cancers.
  • Mitochondrial dysfunction may intersect with various conditions linked to lower urinary tract symptoms.
  • Initial findings indicate higher LUTS rates in patients with inherited mitochondrial disease compared to the general population.
  • The review highlights the need for further research into mechanisms and potential treatments associated with mitochondrial dysfunction.

Abstract

Abstract Purpose Lower urinary tract symptoms (LUTS) can result from several conditions, including but not limited to benign prostatic hyperplasia, diabetes, stress urinary incontinence, and metabolic syndrome. In 2011, it was estimated that nearly 2 billion people (45.2% of the world population) experience one or more LUTS. To date, there is no single underlying mechanism identified in lower urinary tract symptoms or the associated conditions. However, a recent body of evidence has demonstrated that mitochondrial dysfunction may contribute to conditions associated with LUTS. Furthermore, patients with inherited mitochondrial disease exhibit lower urinary tract symptoms at rates above the general population. Given that mitochondrial dysfunction is an under-investigated area of urinary disease research, this review aims to summarize the existing literature in the field. Methods PubMed was used as the primary database for literature search. Keywords included “lower urinary tract symptoms”, “mitochondria”, “urinary dysfunction”; additionally, once identified, further disease-specific searches were performed (e.g., “urinary dysfunction in type 1 diabetes”). Studies published earlier than August 2025 were included, and a specific focus was placed on clinical or human studies. Urologic conditions lacking at least three publications investigating mitochondrial dysfunction were not included; studies examining mitochondrial dysfunction in urologic cancers were also outside the scope of this review. Results and conclusions Mitochondrial dysfunction is a potential novel intersection of diseases associated with LUTS, including aging, metabolic syndrome, diabetes, stress urinary incontinence, benign prostatic hyperplasia, and overactive bladder. While initial studies are promising, more investment into identifying underlying mechanisms and new potential treatments is needed. Additionally, as mitochondrial modulators undergo trial as treatments in other conditions, careful consideration should be given to their potential as treatments for LUTS.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Adrian et al. (2026) studied this question.

synapsesocial.com/papers/69c4cd30fdc3bde44891930bhttps://doi.org/10.1038/s41391-026-01097-5
Ask AI
Helpful
Bookmark
Share
View Full Paper